MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

195.04
-1.68
-0.85%
Closed 17:06 09/18 EDT
OPEN
196.36
PREV CLOSE
196.72
HIGH
196.83
LOW
193.26
VOLUME
1.91M
TURNOVER
--
52 WEEK HIGH
211.90
52 WEEK LOW
166.30
MARKET CAP
116.97B
P/E (TTM)
15.45
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AMGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AMGN News

  • Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
  • Zacks.19h ago
  • Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
  • Zacks.19h ago
  • Amgen Inc. (AMGN) Management Presents at The Bank of America Merrill Lynch Global Healthcare Conference (Transcript)
  • Seeking Alpha - Transcript.22h ago
  • Healthcare And Biotechnology Dashboard - Update
  • Seeking Alpha - Article.1d ago

More

Industry

Pharmaceuticals
+0.10%
Pharmaceuticals & Medical Research
-0.05%

Hot Stocks

Name
Price
%Change

About AMGN

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
More

Webull offers Amgen, Inc. (AMGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.